FDA warns of risk of serious drug induced liver injury with propylthiouracil

Dow Jones Newswires (6/4, Dooren) reports, “The Food and Drug Administration warned doctors Wednesday about the risks of serious liver injury seen with propylthiouracil, a drug used to treat overactive thyroid glands or Graves’ disease.” The agency “said it saw an increased risk of liver injury with propylthiouracil when compared with methimazole.” Amy Egan, the deputy director for safety in FDA’s Division of Metabolism and Endocrinology Products, explained that “patients prescribed propylthiouracil should be closely monitored for symptoms and signs of liver injury, especially during the first six months after initiating therapy.”